MCPH1 inhibits condensin II during interphase by regulating its SMC2-kleisin interface
Abstract
The dramatic change in morphology of chromosomal DNAs between interphase and mitosis is one of the defining features of the eukaryotic cell cycle. Two types of enzymes, namely cohesin and condensin confer the topology of chromosomal DNA by extruding DNA loops. While condensin normally configures chromosomes exclusively during mitosis, cohesin does so during interphase. The processivity of cohesin’s loop extrusion during interphase is limited by a regulatory factor called WAPL, which induces cohesin to dissociate from chromosomes via a mechanism that requires dissociation of its kleisin from the neck of SMC3. We show here that a related mechanism may be responsible for blocking condensin II from acting during interphase. Cells derived from patients affected by microcephaly caused by mutations in the MCPH1 gene undergo premature chromosome condensation but it has never been established for certain whether MCPH1 regulates condensin II directly. We show that deletion of Mcph1 in mouse embryonic stem cells unleashes an activity of condensin II that triggers formation of compact chromosomes in G1 and G2 phases, which is accompanied by enhanced mixing of A and B chromatin compartments, and that this occurs even in the absence of CDK1 activity. Crucially, inhibition of condensin II by MCPH1 depends on the binding of a short linear motif within MCPH1 to condensin II's NCAPG2 subunit. We show that the activities of both Cohesin and Condensin II may be restricted during interphase by similar types of mechanisms as MCPH1's ability to block condensin II's association with chromatin is abrogated by the fusion of SMC2 with NCAPH2. Remarkably, in the absence of both WAPL and MCPH1, cohesin and condensin II transform chromosomal DNAs of G2 cells into chromosomes with a solenoidal axis showing that both cohesin and condensin must be tightly regulated to adjust the structure of chromatids for their successful segregation.
Data availability
HiC sequencing data has been deposited in GEO. (accession number: GSE188988)
-
MCPH1 inhibits condensin II during interphase by regulating its SMC2-kleisin interfaceNCBI Gene Expression Omnibus, GSE188988.
Article and author information
Author details
Funding
Wellcome Trust (107935/Z/15/Z)
- Martin Houlard
- Jonathan Godwin
- Kim Nasmyth
McNair Medical Institute Scholar Award
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
NIH Encyclopedia of DNA Elements Mapping Center Award (UM1HG009375)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
US-Israel Binational Science Foundation Award (2019276)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
Behavioral Plasticity Research Institute (NSF DBI-2021795)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
NSF Physics Frontiers Center Award (NSF PHY-2019745)
- Muhammad S Shamim
- Aviva Presser Aiden
- Erez Lieberman-Aiden
- Lothar Schermelleh
NIH CEGS Award (RM1HG011016-01A1)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
European Research Council (294401)
- Martin Houlard
- Jonathan Godwin
- Kim Nasmyth
Cancer Research UK (26747)
- Martin Houlard
- Jonathan Godwin
- Kim Nasmyth
Wellcome Trust (107457/Z/15/Z)
- Lothar Schermelleh
Wellcome Trust (091911)
- Lothar Schermelleh
Paul and Daisy Soros Foundation
- Muhammad S Shamim
Cancer Research UK (CR-UK C47547/A21536)
- Erin E Cutts
- Alessandro Vannini
Wellcome Trust (200818/Z/16/Z)
- Erin E Cutts
- Alessandro Vannini
Welch Foundation (Q-1866)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#08-133) of the University of Arizona. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Minnesota (Permit Number: 27-2956). All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.
Copyright
© 2021, Houlard et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,851
- views
-
- 419
- downloads
-
- 30
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Pre-mRNA splicing is catalyzed in two steps: 5ʹ splice site (SS) cleavage and exon ligation. A number of proteins transiently associate with spliceosomes to specifically impact these steps (first and second step factors). We recently identified Fyv6 (FAM192A in humans) as a second step factor in Saccharomyces cerevisiae; however, we did not determine how widespread Fyv6’s impact is on the transcriptome. To answer this question, we have used RNA sequencing (RNA-seq) to analyze changes in splicing. These results show that loss of Fyv6 results in activation of non-consensus, branch point (BP) proximal 3ʹ SS transcriptome-wide. To identify the molecular basis of these observations, we determined a high-resolution cryo-electron microscopy (cryo-EM) structure of a yeast product complex spliceosome containing Fyv6 at 2.3 Å. The structure reveals that Fyv6 is the only second step factor that contacts the Prp22 ATPase and that Fyv6 binding is mutually exclusive with that of the first step factor Yju2. We then use this structure to dissect Fyv6 functional domains and interpret results of a genetic screen for fyv6Δ suppressor mutations. The combined transcriptomic, structural, and genetic studies allow us to propose a model in which Yju2/Fyv6 exchange facilitates exon ligation and Fyv6 promotes usage of consensus, BP distal 3ʹ SS.
-
- Biochemistry and Chemical Biology
- Neuroscience
TIMM50, an essential TIM23 complex subunit, is suggested to facilitate the import of ~60% of the mitochondrial proteome. In this study, we characterized a TIMM50 disease-causing mutation in human fibroblasts and noted significant decreases in TIM23 core protein levels (TIMM50, TIMM17A/B, and TIMM23). Strikingly, TIMM50 deficiency had no impact on the steady-state levels of most of its putative substrates, suggesting that even low levels of a functional TIM23 complex are sufficient to maintain the majority of TIM23 complex-dependent mitochondrial proteome. As TIMM50 mutations have been linked to severe neurological phenotypes, we aimed to characterize TIMM50 defects in manipulated mammalian neurons. TIMM50 knockdown in mouse neurons had a minor effect on the steady state level of most of the mitochondrial proteome, supporting the results observed in patient fibroblasts. Amongst the few affected TIM23 substrates, a decrease in the steady state level of components of the intricate oxidative phosphorylation and mitochondrial ribosome complexes was evident. This led to declined respiration rates in fibroblasts and neurons, reduced cellular ATP levels, and defective mitochondrial trafficking in neuronal processes, possibly contributing to the developmental defects observed in patients with TIMM50 disease. Finally, increased electrical activity was observed in TIMM50 deficient mice neuronal cells, which correlated with reduced levels of KCNJ10 and KCNA2 plasma membrane potassium channels, likely underlying the patients’ epileptic phenotype.